Effects of obesity induced by high-fat diet on the pharmacokinetics of cyclosporine A in rats

Biomedicine and Preventive Nutrition

Volumn 1, Issue 3, 2011, Pages 195-201

  Fukushima, Keizo ^a   Yoshida, Kosuke ^b   Ito, Yukako ^b   Takada, Kanji ^b   Sugioka, Nobuyuki ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cyclosporine A; Fatty liver; Pharmacokinetics

Indexed keywords

CHOLESTEROL; CREATININE; CYCLOSPORIN A; LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FATTY LIVER; LIPID DIET; LIVER WEIGHT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; OBESITY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 83655203196     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2011.06.007     Document Type: Article

References (35)

1. Borel J.F., Feurer C., Magnée C., Stähelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977, 32:1017-1025.
2. Martino R., Sureda A., Ayats R., Muñiz-Díaz E., Altés A., Brunet S. Successful treatment of chronic autoimmune neutropenia with cyclosporin A. Haematologica 1994, 79:66-69.
3. Tilney N.L., Milford E.L., Araujo J.L., Strom T.B., Carpenter C.B., Kirkman R.L. Experience with cyclosporine and steroids in clinical renal transplantation. Ann Surg 1984, 200:605-613.
4. Demetris A.J., Lasky S., Van Thiel D.H., Starzl T.E., Dekker A. Pathology of hepatic transplantation: a review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol 1985, 118:151-161.
5. Keogh A., Spratt P., McCosker C., Macdonald P., Mundy J., Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995, 333:628-633.
6. Bacigalupo A., Van Lint M.T., Occhini D., Gualandi F., Lamparelli T., Sogno G., et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991, 77:1423-1428.
7. Hamwi A., Salomon A., Steinbrugger R., Fritzer-Szekeres M., Jäger W., Szekeres T. Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods. Am J Clin Pathol 2000, 114:536-543.
8. Mueller P.W., Delaney V., MacNeil M.L., Caudill S.P., Steinberg K.K. Indicators of acute renal-transplant rejection in patients treated with cyclosporine. Clin Chem 1990, 36:759-764.
9. Minami M., Ohta M., Ohkura T., Ando T., Ohmiya N., Niwa Y., et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 2007, 13:754-760.
10. Kennedy M.S., Deeg H.J., Siegel M., Crowley J.J., Storb R., Thomas E.D. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983, 35:211-215.
11. Wacke R., Rohde B., Engel G., Kundt G., Hehl E.M., Bast R., et al. Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics. Eur J Clin Pharmacol 2000, 56:43-48.
12. Gören S., Karahoca A., Onat F.Y., Gören M.Z. Prediction of cyclosporine A blood levels: an application of the adaptive-network-based fuzzy inference system (ANFIS) in assisting drug therapy. Eur J Clin Pharmacol 2008, 64:807-814.
13. Grundy S.M. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008, 28:629-636.
14. Cameron A.J., Shaw J.E., Zimmet P.Z. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004, 33:351-375.
15. Ford E.S., Giles W.H., Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004, 27:2444-2449.
16. Lemaire M., Tillement J.P. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 1982, 34:715-718.
17. Neiderberger C., Lemaire M., Mauer G. Distribution and binding of cyclosporin in blood and tissues. Transplant Proc 1983, 18:1281-1284.
18. Wasan K.M., Pritchard P.H., Ramaswamy M., Wong W., Donnachie E.M., Brunner L.J. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm Res 1997, 14:1613-1620.
19. Schrieber S.J., Wen Z., Vourvahis M., Smith P.C., Fried M.W., Kashuba A.D., et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 2008, 36:1909-1916.
20. Lickteig A.J., Fisher C.D., Augustine L.M., Aleksunes L.M., Besselsen D.G., Slitt A.L., et al. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 2007, 35:1970-1978.
21. Weltman M.D., Farrell G.C., Hall P., Ingelman-Sundberg M., Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
22. Emery M.G., Fisher J.M., Chien J.Y., Kharasch E.D., Dellinger E.P., Kowdley K.V., et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003, 38:428-435.
23. Anai M., Funaki M., Ogihara T., Kanda A., Onishi Y., Sakoda H., et al. Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats. Diabetes 1999, 48:158-169.
24. Folch J., Lees M., Sloane-Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957, 237:497-509.
25. Fukushima K., Haraya K., Terasaka S., Ito Y., Sugioka N., Takada K. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats. Biol Pharm Bull 2008, 31:1209-1214.
26. Yoshikawa Y., Kato K., Sone H., Takada K. Development and evaluation of noncompartmental pharmacokinetic analysis program WinHARMONY using Visual BASIC language having a function of automatic recognition vs time profile. Rinsho Yakuri 1998, 29:475-487.
27. Eliot L.A., Foster R.T., Jamali F. Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 1999, 16:309-313.
28. Shayeganpour A., Jun A.S., Brocks D.R. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 2005, 26:249-257.
29. Brocks D.R., Ala S., Aliabadi H.M. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 2006, 27:7-16.
30. Aliabadi H.M., Spencer T.J., Mahdipoor P., Lavasanifar A., Brocks D.R. Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function. AAPS J 2006, 8:672-681.
31. Sugioka N., Haraya K., Fukushima K., Ito Y., Takada K. Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats. Biopharm Drug Dispos 2009, 30:532-541.
32. Gupta S.K., Manfro R.C., Tomlanovich S.J., Gambertoglio J.G., Garovoy M.R., Benet L.Z. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 1990, 30:643-653.
33. Gupta S.K., Benet L.Z. High-fat meals increase the clearance of cyclosporine. Pharm Res 1990, 7:46-48.
34. Roberts C.K., Liang K., Barnard R.J., Kim C.H., Vaziri N.D. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X. Kidney Int 2004, 66:1503-1511.
35. Shibata N., Inoue Y., Fukumoto K., Nishimura A., Fukushima K., Yoshikawa Y., et al. Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure. Biol Pharm Bull 2004, 27:384-391.